Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra/AER Causality Link Not Possible - Cantox/CRN

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.

You may also be interested in...



Ephedra Label Warning With Limited PDP Statement Recommended By CRN

The Council for Responsible Nutrition suggests FDA require a label warning format for ephedrine alkaloid-containing products featuring a limited principal display panel declaration that refers consumers to more information on another part of the label

Ephedra Label Warning With Limited PDP Statement Recommended By CRN

The Council for Responsible Nutrition suggests FDA require a label warning format for ephedrine alkaloid-containing products featuring a limited principal display panel declaration that refers consumers to more information on another part of the label

Ephedra Label Warning With Limited PDP Statement Recommended By CRN

The Council for Responsible Nutrition suggests FDA require a label warning format for ephedrine alkaloid-containing products featuring a limited principal display panel declaration that refers consumers to more information on another part of the label

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS092032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel